NOVABONE POROUS-BONE GRAFT SCAFFOLD
K060432 · Novabone Products, LLC · MQV · Apr 4, 2006 · Orthopedic
Device Facts
| Record ID | K060432 |
| Device Name | NOVABONE POROUS-BONE GRAFT SCAFFOLD |
| Applicant | Novabone Products, LLC |
| Product Code | MQV · Orthopedic |
| Decision Date | Apr 4, 2006 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3045 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
NovaBone Porous - Bone Graft Scaffold is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. NovaBone Porous is indicated to be gently packed into bony voids or gaps of the skeletal system (i.e. the extremities and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.
Device Story
NovaBone Porous is a synthetic, resorbable, osteoconductive bone void filler. Composed of calcium phospho-silicate (45S5 Bioglass) particulate fused into a bulk porous scaffold with multidirectional interconnected porosity. Used by clinicians familiar with bone grafting; implanted by packing into non-structural osseous defects. Upon implantation, the device undergoes surface modification to form a calcium phosphate layer; acts as a scaffold for new bone infiltration. Progressively resorbed and replaced by natural bone tissue during healing. Does not provide mechanical support; requires standard internal or external fixation if load-bearing is necessary. Benefits include promoting natural bone regeneration in non-load-bearing gaps.
Clinical Evidence
In vivo study data demonstrated osteoconductive properties with new bone formation at early post-implantation periods and no local or systemic adverse effects. Supporting in vitro data provided. No human clinical trial data reported.
Technological Characteristics
Single-phase bioactive glass (45S5 Bioglass). Bulk porous scaffold with multidirectional interconnected porosity. Osteoconductive, resorbable, non-structural. Biocompatible, inorganic. Designed for manual packing into defect sites.
Indications for Use
Indicated for patients with non-structural bony voids or gaps in the skeletal system (extremities and pelvis) resulting from surgical procedures or traumatic injury. Contraindicated for load-bearing defects or where structural stability is required.
Regulatory Classification
Identification
A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.
Special Controls
*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
Predicate Devices
- NovaBone - Resorbable Bone Graft Substitute (K021336)
- ProOsteon 500R - Resorbable Bone Graft (K990131)
Related Devices
- K052494 — NOVABONE-BIOACTIVE SYNTHETIC GRAFT · Novabone Products, LLC · Nov 3, 2005
- K090731 — NOVABONE POROUS - SYNTHETIC BONE GRAFT SCAFFOLD · Novabone Products, LLC · Apr 15, 2009
- K082672 — NOVABONE PUTTY-BIOACTIVE SYNTHETIC BONE GRAFT · Novabone Products, LLC · Dec 9, 2008
- K021336 — NOVABONE-RESORBABLE BONE GRAFT SUBSTITUTE · Novabone Products, LLC · Jul 25, 2002
- K060728 — NOVABONE PUTTY - BIOACTIVE SYNTHETIC GRAFT · Novabone Products, LLC · May 1, 2006
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for "NOVABONE SYNTHETIC BONE GRAFT PRODUCTS". The word "NOVABONE" is written in large, bold, black letters. There is a starburst design in the middle of the word. Below the word "NOVABONE" is the phrase "SYNTHETIC BONE GRAFT PRODUCTS" written in smaller, black letters.
K060432
# 510(k) Summary NovaBone Porous - Bone Graft Scaffold
02/17/06
# Submitter Information: 1.
| Name: | NovaBone Products, LLC |
|------------|----------------------------------------------------|
| Address: | 13709 Progress Boulevard, #33<br>Alachua, FL 32615 |
| Telephone: | (386) 462-7660 |
| Facsimile: | (386) 418-1636 |
| Contact: | David M. Gaisser |
### Name of Device: 2.
| Trade Name: | NovaBone Porous – Bone Graft Scaffold |
|----------------------|------------------------------------------------------------------------------|
| Common Name: | Osteoconductive Bone Void Filler<br>Synthetic Resorbable Bone Graft Material |
| Classification Name: | Unknown |
### Legally Marketed Predicate Device: 3.
| Predicate #1: | NovaBone - Resorbable Bone Graft Substitute<br>[K021336] |
|---------------|----------------------------------------------------------|
| Predicate #2: | ProOsteon 500R - Resorbable Bone Graft<br>[K990131] |
# 4. Device Description
NovaBone Porous is an osteoconductive bioactive device. It is a one-component, resorbable bone void filler composed of a synthetic calcium phospho-silicate (Bioglass) particulate, fused into a bulk porous form having a multidirectional interconnected porosity. On implantation, NovaBone Porous undergoes a timedependent surface modification, resulting in the formation of a calcium phosphate layer on the device surfaces. The device acts as a scaffold, with new bone infiltrating the porous structure. NovaBone Porous is progressively resorbed and replaced by new bone tissue during the healing process.
### ડ. Intended Use
NovaBone Porous is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. NovaBone Porous is indicated to be gently packed into bony voids or gaps of the skeletal system (i.e. the extremities and These defects may be surgically created osseous defects or osseous pelvis). defects created from traumatic injury to the bone. The product provides an osteoconductive scaffold that resorbs and is replaced with bone during the healing process.
{1}------------------------------------------------
510(k) Premarket Notification NovaBone Products, LLC NovaBone Porous - Bone Graft Scaffold
# Technological Characteristics 6.
The technological characteristics of the NovaBone Porous device are similar to those of the predicates, although not identical. Chemically, the device is comprised of the same material as the NovaBone predicate. Some changes in material crystalline structure have been made during the porous device formation process, but the osteoconductive nature of the device in unchanged. Physically, the device is designed as a bulk, porous osteoconductive space-filling device, similar to the Pro Osteon 500R predicate. It is designed to be gently packed into defect sites and used as a non-structural scaffold for the body's natural healing and bone regeneration process. The device acts as a synthetic, inorganic, biocompatible and osteoconductive scaffold into which new bone will grow.
The NovaBone Porous device is a single-phase bioactive glass (45S5 Bioglass) device. The device indications are the same as those for the predicate devices.
### 7. Warnings and Precautions
NovaBone Porous does not possess sufficient mechanical strength to support loadbearing defects prior to hard tissue ingrowth. In cases of fracture fixation or where load support is required, standard internal or external stabilization techniques must be followed to obtain rigid stabilization in all planes.
NovaBone Porous is intended for use by clinicians familiar with bone grafting and internal/external fixation techniques. NovaBone Porous must not be used to gain screw purchase or to stabilize screw placement.
### 8. Complications
Possible complications are the same as to be expected of autogenous bone grafting procedures. These may include: superficial wound infection, deep wound infection, deep wound infection with osteomyelitis, delayed union, loss of reduction, failure of fusion, loss of bone graft, graft protrusion and / or dislodgement, and general complications that may arise from anesthesia and / or surgery.
### 9. Conclusion
NovaBone Porous functions as a bone void filler for non-structural osseous defects. In vivo study data were presented supporting the osteoconductive nature of the device demonstrating new bone formation at early post-implantation periods, with no evidence of local or systemic adverse effects related to the device observed. Additional supporting in vitro data were supplied.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows a circular logo with the words "DEPARTMENT OF HEALTH AND HUMAN SERVICES" written around the perimeter of the circle. Inside the circle is a stylized image of an eagle with its wings spread. The eagle is facing to the right and has three lines representing its wings. Below the eagle are two wavy lines, possibly representing water.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
APR 4 2006
2006
Nova Bone Products, LLC C/o Mr. David M. Gaisser VP, Operations/RA/QA 13709 Progress Boulevard, #33 Alachua, Florida 32615
Re: K060432
Trade/Device Name: NovaBone Porous -- Bone Graft Scaffold Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable Calcium Salt bone void filler device Regulatory Class: II Product Code: MOV Dated: February 17, 2006 Received: February 22, 2006
Dear Mr. Gaisser:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
# Page 2 - Mr. David M. Gaisser
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120 . Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Herbert Lehman
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
# STATEMENT OF INDICATIONS FOR USE
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
NovaBone Porous - Bone Graft Scaffold Device Name: Device
Indications For Use:
NovaBone Porous - Bone Graft Scaffold is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. NovaBone Porous is indicated to be gently packed into bony voids or gaps of the skeletal system (i.e. the extremities and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.
Prescription Use XX
OR (Per 21 CFR 801.109) Over-The-Counter Use
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) |
|--------------------------------------------------------|
|--------------------------------------------------------|
Division of General, Restorative, and Neurological Devices
510(k) Number K060432